Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.36M Sell
3,865
-25
-0.6% -$8.91K 0.64% 38
2025
Q4
$1.27M Hold
3,890
0.55% 45
2025
Q3
$1.1M Sell
3,890
-25
-0.6% -$7.25K 0.53% 42
2025
Q2
$1.09M Sell
3,915
-100
-2% -$28.3K 0.56% 40
2025
Q1
$1.25M Sell
4,015
-155
-4% -$45.8K 0.67% 37
2024
Q4
$1.09M Sell
4,170
-65
-2% -$19.3K 0.53% 42
2024
Q3
$1.36M Buy
4,235
+300
+8% +$98.1K 0.67% 34
2024
Q2
$1.23M Buy
3,935
+345
+10% +$101K 0.6% 38
2024
Q1
$1.02M Sell
3,590
-269
-7% -$78.7K 0.58% 43
2023
Q4
$1.11M Buy
3,859
+25
+0.7% +$6.81K 0.7% 39
2023
Q3
$1.03M Buy
3,834
+251
+7% +$62.6K 0.76% 38
2023
Q2
$796K Sell
3,583
-212
-6% -$49.2K 0.56% 51
2023
Q1
$917K Sell
3,795
-74
-2% -$18.2K 0.71% 43
2022
Q4
$1.02M Sell
3,869
-23
-0.6% -$6.17K 0.87% 35
2022
Q3
$877K Buy
3,892
+6
+0.2% +$1.45K 0.78% 38
2022
Q2
$946K Buy
3,886
+15
+0.4% +$3.68K 0.76% 37
2022
Q1
$936K Sell
3,871
-137
-3% -$31.5K 0.6% 47
2021
Q4
$902K Sell
4,008
-314
-7% -$66.3K 0.46% 66
2021
Q3
$919K Sell
4,322
-150
-3% -$34.5K 0.49% 63
2021
Q2
$1.09M Sell
4,472
-19
-0.4% -$4.67K 0.58% 53
2021
Q1
$1.12M Hold
4,491
0.67% 44
2020
Q4
$1.03M Buy
4,491
+175
+4% +$40.3K 0.65% 46
2020
Q3
$1.1M Sell
4,316
-149
-3% -$36.9K 0.82% 34
2020
Q2
$1.05M Buy
4,465
+45
+1% +$10.3K 0.89% 34
2020
Q1
$896K Sell
4,420
-815
-16% -$178K 0.9% 33
2019
Q4
$1.26M Buy
5,235
+100
+2% +$22K 0.96% 29
2019
Q3
$994K Buy
5,135
+200
+4% +$38.4K 0.82% 43
2019
Q2
$909K Sell
4,935
-30
-0.6% -$5.37K 0.75% 46
2019
Q1
$943K Buy
4,965
+125
+3% +$23.9K 0.82% 43
2018
Q4
$942K Hold
4,840
0.94% 34
2018
Q3
$1M Buy
4,840
+391
+9% +$77.1K 0.83% 43
2018
Q2
$821K Buy
4,449
+210
+5% +$37.1K 0.72% 49
2018
Q1
$723K Buy
4,239
+105
+3% +$19.3K 0.67% 51
2017
Q4
$719K Buy
+4,134
New +$732K 0.7% 45
2013
Q3
$342K Buy
3,059
+330
+12% +$35.8K 0.44% 76
2013
Q2
$269K Buy
+2,729
New +$283K 0.38% 77

Other funds holding AMGN

AFT Forsyth & Company's AMGN Position: Q1 2026 in Review

AFT Forsyth & Company reduced its Amgen (AMGN) stake by 0.64% in Q1 2026, selling an estimated $8.91K and leaving 3,865 shares worth $1.36M. The position accounts for 0.64% of the portfolio, ranked #38.

AFT Forsyth & Company first reported a position in AMGN in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.36M in Q3 2024. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • AFT Forsyth & Company held 3,865 shares of Amgen worth $1.36M as of Q1 2026.
  • AFT Forsyth & Company sold 25 Amgen shares in Q1 2026, an estimated $8.91K.
  • Amgen made up 0.64% of AFT Forsyth & Company's portfolio in Q1 2026, its #38 holding.
  • AFT Forsyth & Company first reported a position in Amgen in Q2 2013 and has held it in 36 quarters since.
  • AFT Forsyth & Company's Amgen position peaked at $1.36M in Q3 2024.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on AFT Forsyth & Company's 13F filing for Q1 2026, filed 14 May 2026.